Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope
- PMID: 28790381
- PMCID: PMC5548917
- DOI: 10.1038/s41598-017-08037-3
Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope
Abstract
Immunotoxins (ITs), which consist of antibodies conjugated to toxins, have been proposed as a treatment for cancer and chronic infections. To develop and improve the ITs, different toxins such as ricin, have been used, aiming for higher efficacy against target cells. The toxin pulchellin, isolated from the Abrus pulchellus plant, has similar structure and function as ricin. Here we have compared two plant toxins, recombinant A chains from ricin (RAC) and pulchellin (PAC) toxins, for their ability to kill HIV Env-expressing cells. In this study, RAC and PAC were produced in E. coli, and chromatographically purified, then chemically conjugated to two different anti-HIV monoclonal antibodies (MAbs), anti-gp120 MAb 924 or anti-gp41 MAb 7B2. These conjugates were characterized biochemically and immunologically. Cell internalization was studied by flow cytometry and confocal microscopy. Results showed that PAC can function within an effective IT. The ITs demonstrated specific binding against native antigens on persistently HIV-infected cells and recombinant antigens on Env-transfected cells. PAC cytotoxicity appears somewhat less than RAC, the standard for comparison. This is the first report that PAC may have utility for the design and construction of therapeutic ITs, highlighting the potential role for specific cell targeting.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures






Similar articles
-
Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.J Virol. 2024 Oct 22;98(10):e0064724. doi: 10.1128/jvi.00647-24. Epub 2024 Sep 16. J Virol. 2024. PMID: 39283123
-
Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.J Virol. 2017 Jan 18;91(3):e01955-16. doi: 10.1128/JVI.01955-16. Print 2017 Feb 1. J Virol. 2017. PMID: 27852851 Free PMC article.
-
In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.J Immunol. 1991 Jun 15;146(12):4315-24. J Immunol. 1991. PMID: 1710247
-
Immunotoxins up to the present day.Biosci Rep. 1989 Apr;9(2):139-56. doi: 10.1007/BF01115993. Biosci Rep. 1989. PMID: 2669993 Review.
-
Toxin-labeled monoclonal antibodies.Curr Pharm Biotechnol. 2001 Dec;2(4):313-25. doi: 10.2174/1389201013378635. Curr Pharm Biotechnol. 2001. PMID: 11762413 Review.
Cited by
-
Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.Toxins (Basel). 2023 Dec 13;15(12):699. doi: 10.3390/toxins15120699. Toxins (Basel). 2023. PMID: 38133203 Free PMC article. Review.
-
Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.Toxins (Basel). 2020 Oct 15;12(10):658. doi: 10.3390/toxins12100658. Toxins (Basel). 2020. PMID: 33076544 Free PMC article. Review.
-
Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.Sci Adv. 2022 May 6;8(18):eabm3948. doi: 10.1126/sciadv.abm3948. Epub 2022 May 4. Sci Adv. 2022. PMID: 35507661 Free PMC article.
-
Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.Toxins (Basel). 2020 Mar 9;12(3):167. doi: 10.3390/toxins12030167. Toxins (Basel). 2020. PMID: 32182799 Free PMC article. Review.
-
Antiviral Activity of Ribosome-Inactivating Proteins.Toxins (Basel). 2021 Jan 22;13(2):80. doi: 10.3390/toxins13020080. Toxins (Basel). 2021. PMID: 33499086 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous